Home > Name List By s > Sulindac Germany

CAS No 38194-50-2 , Sulindac Search by region : Germany

  • Name: Sulindac
  • Synonyms: (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid;Sulindac;-;
  • CAS Registry Number:
  • Transport: 3249
  • Density: 1.38 g/cm3
  • Refractive index: 1.672
  • Water Solubility: Soluble in DMSO or aqueous bases.
  • Safety Statements: R22
  • Hazard Symbols: Xn: Harmful;
  • EINECS: 253-819-2
  • Molecular Weight: 356.41
  • InChI: InChI=1/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
  • Risk Statements: R22
  • Molecular Formula: C20H17FO3S
  • Molecular Structure:CAS No:38194-50-2 Sulindac

Select to

38194-50-2 SULINDAC

  • Germany CHEMOS GmbH [Manufacturer]
  • Tel: 0049 9402/9336 0
  • Fax: 0049 9402/9336 13
  • Address: CHEMOS GmbH
    Werner-von-Siemensstr. 3
    93128 Regenstauf
    Germany null,nullGermany
Contact Supplier

38194-50-2 SULINDAC

  • Germany BIOTREND Chemikalien GmbH [Manufacturer]
  • Tel: ++49 (0)2 21 9 49 83 20
  • Fax: ++49 (0)2 21 9 49 83 25
  • Address: BIOTREND Chemikalien GmbH
    Eupener Str. 157
    D - 50933 Cologne
    Germany null,nullGermany
Contact Supplier

Select to

References of Sulindac
Title: Sulindac
CAS Registry Number: 38194-50-2
CAS Name: (1Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
Synonyms: cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
Manufacturers' Codes: MK-231
Trademarks: Aflodac (Janus); Algocetil (Francia); Arthrocine (Merck & Co.); Artribid (Merck & Co.); Citireuma (CT); Clinoril (Merck & Co.); Clisundac (Lagap); Reumofil (Ausonia); Reumyl (Lenza); Sudac (Errekappa); Sulinol (ICT); Sulreuma (Von Boch)
Molecular Formula: C20H17FO3S
Molecular Weight: 356.41
Percent Composition: C 67.40%, H 4.81%, F 5.33%, O 13.47%, S 9.00%
Literature References: Non-steroidal anti-inflammatory drug. Prepn: T.-Y. Shen et al., DE 2039426; eidem, US 3654349 (1971, 1972 both to Merck & Co.). Stereospecific synthesis: R. F. Shuman et al., J. Org. Chem. 42, 1914 (1977); enantioselective synthesis: A. R. Maguire et al., Synlett 2001, 41. 13C-NMR study: A. W. Douglas, Can. J. Chem. 56, 2129 (1978). Metabolism and disposition: H. B. Hucker et al., Drug Metab. Dispos. 1, 721 (1973). HPLC determn in biological fluids: D. G. Musson et al., J. Pharm. Sci. 73, 1270 (1984). Book: Current Concepts on Anti-inflammatory Drugs, K. Miehlke, Ed. (Biomedical Information Corp., New York, 1980) 240 pp. Review of pharmacology and efficacy in rheumatic disease: R. N. Brogden et al., Drugs 16, 97-114 (1978); in treatment of colorectal polyps: F. Tonelli et al., Dig. Dis. 12, 259-264 (1994). Review of clinical pharmacokinetics: N. M. Davies, M. S. Watson, Clin. Pharmacokinet. 32, 437-459 (1997).
Properties: Yellow odorless crystals from ethyl acetate, mp 182-185° (dec). uv max (methanolic 0.1N HCl): 327, 285, 256, 226 nm (E1%1cm 375, 420, 410, 540). pKa (25°) 4.7. Sparingly sol in methanol, U.S.P. alcohol; slightly sol in ethyl acetate. Practically insol in water at pH <4.5. Soly increases with rising pH to ~3.0 mg/ml at pH 7. Stable in aq acid and base. Solid stable for at least three days in air at 100°.
Melting point: mp 182-185° (dec)
pKa: pKa (25°) 4.7
Absorption maximum: uv max (methanolic 0.1N HCl): 327, 285, 256, 226 nm (E1%1cm 375, 420, 410, 540)
Therap-Cat: Anti-inflammatory.
Keywords: Anti-inflammatory (Nonsteroidal); Arylacetic Acid Derivatives.